Free Trial
NASDAQ:THTX

Theratechnologies Q2 2025 Earnings Report

Theratechnologies logo
$3.19 -0.02 (-0.62%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$3.20 +0.00 (+0.16%)
As of 08/8/2025 05:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Theratechnologies EPS Results

Actual EPS
-$0.09
Consensus EPS
-$0.01
Beat/Miss
Missed by -$0.08
One Year Ago EPS
N/A

Theratechnologies Revenue Results

Actual Revenue
$17,729.00 billion
Expected Revenue
$24.30 million
Beat/Miss
Beat by +$17,728.98 billion
YoY Revenue Growth
N/A

Theratechnologies Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Wednesday, July 9, 2025
Conference Call Time
8:30AM ET

Upcoming Earnings

Theratechnologies' Q3 2025 earnings is scheduled for Thursday, October 9, 2025, with a conference call scheduled at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Theratechnologies Earnings Headlines

A new rule goes live in July — and the banks are quietly crushing it
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
Theratechnologies Inc. (THTX) - Yahoo Finance
See More Theratechnologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Theratechnologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Theratechnologies and other key companies, straight to your email.

About Theratechnologies

Theratechnologies (NASDAQ:THTX), a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

View Theratechnologies Profile

More Earnings Resources from MarketBeat